Signaling Pathways and Emerging Therapies in Multiple Myeloma

Vijay Ramakrishnan, Anita D’Souza

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Multiple myeloma (MM) is a devastating malignancy of antibody-producing plasma cells. In the absence of a single unifying genetic event contributing to disease manifestation, efforts have focused on understanding signaling events deregulated in myeloma plasma cells. MM cells are dependent on both cellular and non-cellular components of the tumor microenvironment such as bone marrow stromal cells, endothelial cells, and cytokines such as interleukin 6 (IL6), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) for their growth and survival. The cumulative effect of such interactions is the aberrant activation of numerous signal transduction pathways within the MM plasma cells leading to uncontrolled growth and prevention of apoptosis. Here, we will review our current understanding of some of the key signal transduction pathways dysregulated in MM and emerging therapies targeting these pathways in MM.

Original languageEnglish (US)
Pages (from-to)156-164
Number of pages9
JournalCurrent Hematologic Malignancy Reports
Issue number2
StatePublished - Apr 1 2016


  • Akt
  • Multiple myeloma
  • NF-κB
  • Signaling
  • Signaling inhibitors
  • mTOR

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Signaling Pathways and Emerging Therapies in Multiple Myeloma'. Together they form a unique fingerprint.

Cite this